2023-06-26 16:41:39
After Androcur or Luteran, a vast study by the National Medicines Agency, published on Monday June 26, shows that three other products from the same family present a “significant increased risk” of developing meningiomas. But all progestogens are not affected.
“Androcur”: for several years, this prescribed treatment once morest endometriosis has also been synonymous with scandal and a high risk of meningioma, a form of brain tumor that can cause serious disabilities even if it is benign. Subsequently, a link had also been established with two other drugs of the same family, Lutéran and Lutényl. A doubt resided, since, on all progestogens: at the beginning of the year, the National Agency for the Safety of Medicines and Health Products (ANSM) had even called on doctors to remain vigilant. She answers it in a large study published this Monday, June 26, with contrasting conclusions: not all treatments are concerned, but new ones have been identified.
“There are three new products for which our study finds a significant increased risk of meningioma, but a set of other products for which we conclude that there is none”, summarizes Alain Weill, public health doctor. He supervised this study carried out retrospectively among a hundred thousand women for the scientific group EPI-PHARE, formed by the ANSM and the National Health Insurance Fund (Cnam). Thus three progestins – Colprone (medrogestone), Depo Provera (medroxyprogesterone) and Surgestone (promegestone) – multiply the risk of meningioma.
Colprone, a widely distributed treatment
Progestins are drugs widely used as a contraceptive, in certain pathologies such as endometriosis, hirsutism, severe acne, in support of menopause, in the face of problems such as infertility. If two of the three newly identified treatments are no longer or little prescribed, the case of Colprone is more problematic: it is given to several tens of thousands of patients. And quadruples the risk of meningioma.
However, the study shows that there is no risk associated with treatments that are much more prescribed. This is the case of Utrogestan (progesterone) and Duphaston and Climaston (dydrogesterone), prescribed to hundreds of thousands of patients. There is also no proven risk associated with the use of an IUD delivering progestins – a device which, according to researchers, is probably used by more than 500,000 women in France.
1687827185
#ANSM #identifies #excess #risk #meningiomas #additional #treatments #Liberation
